

DRAFT

RADIATION EFFECTS IN MAN: MANIFESTATIONS  
AND THERAPEUTIC EFFORTS

REPORT PERIOD

April 1, 1971 through March 31, 1972

Eugene L. Saenger, M.D.  
Edward B. Silberstein, M.D.  
Bernard S. Aron, M.D.  
Harry Horwitz, M.D.  
James G. Kereiakes, Ph.D.  
I-Wen Chen, Ph.D.  
Carolyn Winget, M.A.  
Goldine C. Gleser, Ph.D.

HEADQUARTERS

DEFENSE NUCLEAR AGENCY  
WASHINGTON, D.C. 20305

PREPARING AGENCY

University of Cincinnati College of Medicine  
Cincinnati General Hospital  
Cincinnati, Ohio 45229

Contract No. DASA-01-69-C-0131

This research has been sponsored by the Defense Nuclear Agency NWER  
Subtask MC009.

SECTION 2

CONTENTS

Thermography as a Radiobiological Dosimeter-----	38
Materials and Methods-----	38
Results and Discussion-----	41
Tables-----	44
References-----	49

Tables

1. Normal Maximum Differences in Symmetric Areas of the Body-----	44
2. Skin Temperature of Patients Receiving Cobalt-60 Radiotherapy - Patient 1 and 2-----	45
Patient 3 and 4-----	46
Patient 5 and 6-----	47
3. Breast Cancer-----	48

## FOREWORD

This report was prepared by the following members of the University of Cincinnati College of Medicine.

Eugene L. Saenger, M.D.  
Edward B. Silberstein, M.D.  
Bernard S. Aron, M.D.  
Harry Horwitz, M.D.  
James G. Kereiakes, Ph.D.  
I-Wen Chen, Ph.D.  
Carolyn Winget, M.A.  
Goldine C. Gleser, Ph.D.

The research was supported by the Medical Directorate, Defense Nuclear Agency, Washington, D.C. under Contract No. DASA-01-69-C-0131. The Project Officer for the contract is Dr. Myron Varon.

These studies were performed in conformation with the "recommendations guiding doctors in clinical research" as stated in the Declaration of Helsinki of the World Medical Association (1964) and have been approved by the Committee on Human Research of the University of Cincinnati College of Medicine.

Research was conducted according to the principles enunciated in the "Guide for Laboratory Animal Facilities and Care," prepared by the National Academy of Sciences, National Research Council.

INTRODUCTION:

During the present contract period April 1, 1971 through March 31, 1972, we analyzed in great detail the results of whole and partial body radiation in the cancer patients treated between February 19, 1960 and August 31, 1971. Section 1 of this report comprises the scientific communication presented at the meeting of the American Roentgen Ray Society in Washington on October 3, 1972. This report has been accepted for publication in the American Journal of Roentgenology, Radium Therapy and Nuclear Medicine.

Section 2 of this report presents a study of the use of thermography to estimate radiation dose to skin in patients receiving  $^{60}\text{Co}$  therapy. This method was not successful in identifying skin erythema or increased skin temperature even if such effects were present.

## SECTION 1

### WHOLE BODY AND PARTIAL BODY RADIOTHERAPY OF ADVANCED CANCER

#### Introduction

The purpose of these investigations has been to improve the treatment and general clinical management and if possible the length of survival of patients with advanced cancer. Systemic effects of radiation therapy have been given particular attention in our work.

In the period February 19, 1960, through August 31, 1971, 85 adults were given whole or partial body radiation as therapy for far advanced cancer. This paper will report on the survival of patients in three categories: colon, lung and breast. Prophylactic whole body radiation therapy was given to 3 children with localized Ewing's sarcoma and this experience will be discussed briefly. Investigations of biochemical, cytological and psychological tests have been reported elsewhere.<sup>8,11,50</sup> Our experience with the adjuvant use of autologous bone marrow will also be described.

#### Animal Studies

The animal investigations basic to our work stem from the studies of Hollcroft et al.<sup>13,14,15</sup> These authors demonstrated better tumor regression when whole body radiation was preceded by localized radiation therapy than when localized radiation was given alone both for lymphoma and carcinoma in mice. The studies of Jacobson et al.<sup>18,19</sup> showed the importance of shielding of the spleen and other organs and parts of the body in preventing high dose radiation lethality in the mouse.

Brief Review of Total Body Radiation in Man:

Total body irradiation was first employed in 1923 by Chaoul and Lange.<sup>7</sup> Its use in 270 cases over the next 20 years was reviewed by Medinger and Craver.<sup>32</sup> These authors found the greatest palliation in the lymphomas and myeloproliferative diseases, but also noted improvement in multiple myeloma. Thirty-five patients with advanced carcinoma or sarcoma were included in this series, most of them receiving their total body radiation between 1931 and 1933.

Loeffler et al.<sup>30</sup> compared total body radiation in single doses up to 150 R with nitrogen mustard and triethylene melamine and found that neither chemotherapy nor radiotherapy differed in hematologic effects, but that the patients receiving radiation did not experience the malaise of varying severity noted by all patients receiving the chemotherapeutic agents. Subjective improvement was noted only in the radiotherapy group.

Collins and Loeffler<sup>9</sup> gave total body irradiation in single exposure up to 200 roentgens and found this form of systemic therapy "a useful addition to the management of advanced cancer." The malignancies treated included lymphoma, chronic myelogenous leukemia and multiple myeloma.

Interest in total body radiation in the treatment of Ewing's sarcoma, a tumor of children which carries a high mortality, has been aroused by reports from Milburn et al.,<sup>33</sup> Jenkin et al.,<sup>21</sup> and Rider and Hasselback.<sup>39</sup> In a small series so treated, survival appeared to be moderately improved compared to larger series treated by conventional local radiotherapy and/or ablative surgery. These groups felt further evaluation of this form

of therapy to be most important.

Additional data have been published by the Medical Division of Oak Ridge Associated Universities,<sup>1</sup> concerning total body radiation therapy of lymphoproliferative and myeloproliferative disease.

Summaries of the frequent use of total body irradiation for the therapy of leukemia appear in an article by Buckner et al.,<sup>4</sup> and in a comprehensive review of bone marrow transplantation by Bortin.<sup>3</sup>

Whole body radiation in routine clinical therapy has been and is currently used for leukemia,<sup>23,53</sup> lymphoma,<sup>22-26,53</sup> Hodgkin's disease,<sup>3</sup> polycythemia vera,<sup>6</sup> cancer of breast,<sup>31</sup> cancer of thyroid,<sup>5</sup> cancer of prostate,<sup>10,31</sup> and multiple myeloma.<sup>9,32</sup> Such therapy may be given by external radiation therapy (as in this particular study) or in the form of various radionuclides.

#### Study Design:

The studies reported here were initially considered as being in Phase I (to determine whether the treatment was toxic or not) and subsequently as Phase II (whether treatment appears effective or not but without controls). In reviewing these data it has been possible to find some comparable material in the literature. In one category, cancer of bronchus, comparable data were available in our institution.

#### Informed Consent and Institutional Review:

All patients gave informed consent in accordance with directives of the Faculty Research Committee of the University of Cincinnati College of Medicine and those of the National Institutes of Health. The use of formal informed consent forms in this study antedated the above requirements by two years. The project is reviewed and approved regularly by the above Committee.

### Eligibility of Patients

Patients become eligible for this form of treatment if they have advanced cancer for whom cure could not be anticipated. Three children with localized Ewing's tumor at Children's Hospital were given whole body radiation as part of the curative attempt after the primary tumor had been ablated with local radiotherapy.

Biopsy proof of the malignancy has been established in all instances. Clinical data in each case have been reviewed by several physicians to be certain that the tumor had indeed extended from its primary site and that curative therapy was not applicable. This preliminary evaluation is followed by an observation period of 7-14 days to observe the general condition of the patient and to carry out baseline laboratory tests to be as certain as possible that the condition of the patient is relatively stable. Frequently this determination is difficult since the patients have serious illnesses of long standing and often have had considerable previous therapy.

Patients remain in the hospital as long as is necessary. Prior to the use of autologous bone marrow transfusion, hospitalization was occasionally as long as 8-10 weeks. Length of stay was also dependent upon the severity of the clinical manifestations stemming from the cancer. With the use of partial body radiation and bone marrow infusion, hospitalization has been greatly shortened. The follow-up procedure is continuous during the lifetime of the patient.

A total of 112 subjects were initially entered in the study through August 31, 1971. During the screening period of 7-14 days, 24 of them

(21%) were not continued in the study and did not receive whole or partial body radiation. Chief among the reasons for elimination was an indication in the pre-treatment phase that some risk from wide-field radiation might ensue or that another method of treatment was considered preferable. In some, a very rapid progress of the disease made inclusion undesirable. The treatment was completed in 85 adults and 3 children between April 1960 and August 31, 1971. Three patients have received two separate courses of treatment in this program. Follow-up time for survivors is reported through August 31, 1972.

Patient Dosimetry:

The radiation is delivered by a Cobalt-60 teletherapy unit under the following exposure conditions. The beam is directed horizontally at a wall 342 cm away with the midline of the patient at 286 cm from the source. For whole body exposures, the radiation beam size for the 60% isodose curve at the patient midline distance is a square approximately 120 cm x 120 cm. The patient is placed in the sitting position with legs raised and head tilted slightly forward. Radiation is given by delivering half the specified exposure laterally through one side of the patient, the patient is then turned and the other half exposure delivered laterally through the other side. The combined dose of the two radiation fields provides a good homogeneous dose distribution through the patient. The maximum variation in lateral dose distribution was +13 percent for one patient who had a lateral trunk dimension of 36 cm.

The exposure to the patient is determined using a percentage depth dose table corrected for the source-to-skin distance used for the patient. Using

the corrected depth dose at patient midline (1/2 lateral dimension at the trunk in the plane of the xiphoid) and a conversion factor of 0.957 rads/Roentgen for Cobalt 60 gamma radiation, the midline air exposure required to give a desired midline absorbed dose in rads is calculated. The validity of this procedure was established with measurements in an Alderson Rando Phantom using thermoluminescence dosimeters. Over the course of the study, the air exposure rates at the distance indicated above varied from 3R-6R per minute.

For individuals receiving partial body radiation, the teletherapy collimator is used to restrict the beam. The xiphoid is used as the boundary of the field for upper and lower body exposures. The lateral dimensions of the patient in the plane of the xiphoid is again used for calculating the desired midline dose. As for the whole body exposure, the dose is delivered bilaterally. Additional information on the dosimetry aspects of this study has been published by Kereiakes et al.<sup>27</sup>

#### Analysis of Survival Data:

In considering the survival data there was a lack of consistent selection bias both in recommendation that a patient be eligible for treatment and in regard to the dose. The principal investigator had no part in determination of therapy in any given case except for outlining the general principles of the therapeutic regime. The choice in the case of each patient was made by several radiation therapists, three having been associated with the project during the 10 year period. In addition, two internists have had active roles in the selection and medical care of each patient. The dose of radiation to be given was decided upon by the radiation therapist in consultation with the internist.

There are three categories of patients (those with carcinoma of the colon, lung and breast) which are large enough to permit some analyses of survival. Each group will be discussed separately.

Survival data are given in days from the diagnosis of far advanced disease since this convention has been used frequently in the literature and permits comparison of our survival data with published reports.

Cancer of the Colon and Rectum:

Twenty-nine patients with this tumor comprised the largest single category (Table 1). In all cases the patients were classed as far advanced and in a few instances as terminal. Four patients were not included in the study for medical reasons, or because the patients themselves declined participation in the study.

In order to make an appropriate comparison, several published series were reviewed. Series of cases of colon cancer metastatic to liver were utilized, since they were the best found by us with appropriate time periods of metastasis available for comparison. Stearns and Binkley,<sup>51</sup> in 32 patients with colon cancer with liver metastases, found a median survival time of 11 months after palliative resection of the primary tumor; in 28 of their patients in whom only biopsy or diversion was performed, the median survival was 8 months. In 353 patients with untreated colon cancer metastatic to liver, Pestana et al.<sup>37</sup> reported a median survival of nine months. Figure 1 presents an analysis of 177 patients with liver metastases and no subsequent therapy reported by Jaffe et al.<sup>20</sup> There is also a group of 61 patients reported by Rapoport et al. treated with 5 fluorouracil.<sup>38</sup> The twenty-two patients in our series with proven metastatic carcinoma of the colon to the liver treated by radiation

are also shown in Figure 1.

The median survival time for untreated patients was 146 days; for patients treated only with 5 fluorouracil, 255 days; and, among our patients with liver metastases, 391 days (Table 2). A life table analysis was performed and indicates that the treatment given to our patients was approximately equivalent to the group given 5 fluorouracil. There was no evidence that the median survival time was shortened by total or partial body radiation (Figure 1). It should be appreciated that five of our patients had received or are receiving 5 fluorouracil in addition to the radiation therapy (3 of these with liver metastases.)

The median survival for the entire group of twenty-nine patients (twenty-two with liver metastases) was 327 days.

#### Cancer of the Bronchus:

This group of fifteen patients (Table 3) had far advanced disease with distant metastases at the time of treatment. The best comparison group was from our own institution reported by Horwitz et al.<sup>16</sup> The median survival of the 15 patients receiving whole body radiation was 193 days from the time of diagnosis. The median survival of 61 patients seen at Cincinnati General Hospital from December, 1961, to June, 1964, was 135 days. In 15 of the 17 cases with distant metastases excluded by Horwitz et al. from their study (see caption to Figure 2), the median survival was 32 days.

This last group of patients with distant metastases constitutes the most appropriate comparison group. When the median survival of fifteen\*

\*Two of the 17 patients excluded in the Horwitz et al. study were treated by whole body radiation.

patients mentioned by Horwitz et al. is compared with the 15 patients treated by whole body radiation, the survival times are significantly different (Chi square 11.63,  $p < 0.005$ ). (See Figure 3).

Ewing's tumor:

This sub group of 3 patients constituted the only one in which an attempt at curative therapy was made; all 3 patients are surviving. The times of survival are 854, 1243 and 1553 days from the time of diagnosis to August 31, 1972. The patient with the longest survival has recently developed a solitary pulmonary metastasis. The use of whole body radiation to eliminate small clumps of cells in the disease has been reported by others.<sup>21,33</sup>

A fourth patient with Ewing's tumor had pulmonary metastases when first seen. Therapy in that case was only palliative.

Cancer of the Breast:

In 15 cases treated by us the median survival from diagnosis to death was 479 days and after treatment to death was 446 days (Table 4). Two comparable reports in the literature include the one by the Committee on Estrogens and Androgens<sup>52</sup> and the other by Samp and Ansfield using 5 fluorouracil.<sup>49</sup> Again a life table analysis was done for our 15 patients and indicates that the survival of our patients appears somewhat better than that of the patients treated solely by estrogens and androgens but not quite as good as the group treated with 5 fluorouracil (Figure 4). The patients survive longer than those receiving the "standard therapy" as described by Samp and Ansfield; this includes appropriate

administration of estrogen and androgen, oophorectomy, local radiation, adrenalectomy and hypophysectomy.

Other Cancers:

A remaining group of 25 cases reflected several different kinds of cancer. It is not possible to make an analysis of these at this point since the individual case groups are too small to warrant this.

. DISCUSSION

Relation of Radiation Therapy to Patient Death:

Some analyses can be made which give information on this point.

The doses of whole body radiation given could initiate only the hematological form of the acute radiation syndrome. In the healthy individual, after prodromal symptoms of malaise and vomiting lasting about 6-48 hours, there is a latent period lasting until 18-21 days after exposure. At this time there is a marked rapid fall in white cells and platelets and a less rapid fall of red cells reaching a nadir at 30-40 days and then recovering. These changes are associated frequently with episodes of infection and bleeding. Epilation will occur at doses over 300 rads.

Many of these patients had received much radiation and chemotherapy prior to total or partial body treatment and in many cases this treatment was followed immediately by planned local therapy to various portions of the body.

If one assumes that all severe drops in blood count and all instances of hypo-cellular or acellular marrow at death were due only to radiation and not influenced by the type or extent of cancer and effects of previous therapy, then one can identify 8 cases in which there is a possibility of the therapy contributing to mortality. Of this subgroup, 2 patients received localized radiation between total body radiation and death at 31 and 32 days, respectively. Two had extensive previous chemotherapy and one also had local radiotherapy. In two other cases, autologous marrow transfusion was unsuccessful because the pre-radiation marrow was hypo-cellular. Both of these latter patients had had intensive localized radiation and one had received intensive chemotherapy.

Of the 19 patients who died within 20-60 days, 11 showed clear evidence of well functioning marrow with steady or rising white blood counts and absence of bleeding and infection at the time of death.

The time from diagnosis to death of the 24 patients entered in the study who were not treated has been analyzed. There were 4 who died in a 20-60 day interval:

	<u>No. of Deaths in 20-60 days</u>	<u>Patients surviving or dying at other times</u>	<u>Total</u>
Patients Not Given Radiation	4	20	24
Patients Given Radiation	19	63	82

Fisher's exact probability test yields a p value of 0.16, indicating that there is no difference between the two groups. Therefore one

may conclude that in other patients described, the effect of whole and partial body radiation therapy was less important in contributing to death than was the extent of disease in these patients. Another interpretation would be that a physician selecting far advanced cancer patients for a given treatment would have about the same degree of difficulty in selecting any form of treatment for these very ill patients. The same probabilities,  $p=0.19$ ,  $0.2$  and  $0.21$  are found for patients dying between 0 and 20 days post treatment, from 0-60 days and from 20-40 days, when compared to the untreated group. Current status of survival for these 88 treated patients are as follows:

Prophylactic Therapy (Ewing's Tumor)	3
Others surviving as of August 31, 1972	7
Deaths possibly attributable to radiation	8
Deaths attributable to tumor	<u>70</u>
	88

Reactions from Treatment and Effects of Palliation:

The acute radiation syndrome is divided into 3 stages. In stage 1, prodromal, nausea and vomiting of a transient nature occur. These complaints are often highly subjective; therefore they are not discussed with the patient before treatment. The analysis of our 88 treated patients shows that 44% experienced no symptoms at all, that 27% had transient nausea and vomiting within 3 hours, 14% within 6 hours and 3% within 12 hours. In only 4 patients (4%) were the nausea and vomiting of a severe nature (Table 5). These symptoms are no greater than found after surgery or after treat-

ment with cancer chemotherapy drugs, the reactions of which are often far more severe than those from these kinds of radiation therapy. Lahiri et al.<sup>29</sup> observed that when 5-fluorouracil (5-FU) is given orally at a dose of 15 mg/kg daily for 6 days, and then weekly at the same dose, nausea, vomiting, diarrhea or stomatitis are found in 55% of the patients treated, and marrow depression is observed in 50%. A recent study by the Western Cooperative Cancer Chemotherapy Group, employing 5-FU without a loading dose at 15 mg/kg/wk for a month, reported mild to major gastrointestinal or hematologic toxicity in 85.5% of 430 patients.<sup>17</sup> Higgins et al.<sup>12</sup> in treating cancer of the colon using 12 mg/kg of 5-FU intravenously for 5 successive days, observed that 27.9% of 359 patients experienced a toxic reaction. The same group reported one or more surgical complications following resection of colon carcinoma in 29.6% of 433 patients. Parsons et al.<sup>35</sup> note that 61-72% of patients suffering from so called radiation sickness responded favorably to placebo medication indicating that suggestibility may have a big part to play in the appearance and control of these symptoms. Mukherji et al.<sup>34</sup> in evaluating the effectiveness of a combination of four drugs in the treatment of 23 patients with lymphosarcoma and reticulum cell found severe myelosuppression in 4 patients (17%) and possibly attributed this depression to their deaths from infection.

During the latent period of 18-21 days the patient is asymptomatic. The period of manifest illness then begins with evidence of malaise, infection and bleeding. These findings occur only with whole body radiation and not with partial body treatment. Also when marrow is successfully replaced these findings do not occur.

In regard to palliation, a review of patient records show that some palliation was achieved in 56% and that 31% were made neither better nor worse (see Table 6). In another 3 cases we were unable to obtain follow-up history concerning palliative effects. The three cases of Ewing's tumor are not included in this table as therapy was prophylactic.

Possible Unique Mechanisms of Whole and Partial Body Radiotherapy

Whole body radiation in the doses reported herein could be effective against cancer in several ways: 1] Alteration of the immune mechanism of the body altering the balance in favor of the host; 2] By a direct effect on the metabolism of the cancer cells. In this case wide-field radiotherapy would have one advantage over drug therapy since it would reach all cancer cells without depending upon blood supply, or chemical and pharmacological distribution.

Partial body radiation could be compared to regional isolation perfusion with anti-neoplastic drugs, again being certain to reach all tumor cells within the irradiated volume and lacking the more hazardous systemic effects of total body radiation.

The effectiveness of both methods may be explained by the fact that small tumor foci are more sensitive to treatment than large foci and that single cancer cells are more susceptible than clumps of cells.

## PSYCHOLOGICAL AND PSYCHIATRIC EVALUATION OF PATIENTS

A unique and important aspect of the research work in this project has been the attempt to evaluate and distinguish between the manifestations of cancer and the effects of radiation therapy in regard to psychological and psychiatric changes. For example, others have reported on personality types in certain cancers<sup>2</sup> but no studies were presented investigating the effects of treatment.

In 1969, we reported on the effect of total and partial body radiation on the cognitive and emotional processes of 16 patients.<sup>11</sup> This number has been increased to 43. These studies consisted of administration of a battery of tests to each patient in the pre-treatment phase, during sham and actual treatment and during a 6 week post-treatment period. Tests which have been utilized included the Halstead Battery, Wechsler Bellevue Adult Intelligence Scale, some tests of intellectual impairment modified from Reitan, and the 5 minute verbal content test of Gottschalk and Gleser. There has been some change in the several tests which we have been using during this phase of the total project, i.e. not all tests have been used continually.

In the baseline data of 39 patients tested, the median intelligence quotient was 87 and the mean also 87. There were 41% of subjects with I.Q. values of 95-116, 47% between 71-94 and 12% between 63-70. The distribution of intelligence factors as measured by several tests is representative of the population served by the General Hospital.

It is clear that the intensive study and above testing has had a helpful effect in increasing the level of motivation to cooperate, as exhibited by all patients so studied.

The need for careful handling of the cancer patient by all members of the medical team is emphasized by the consistent evidence of depression over the 7 week study period. The depression is lessened with clinical improvement and attention to patient needs. It is also less in patients with long survival (over 100 days) as would be expected. Similarly, hope is directly related to survival. Anxiety dips sharply during sham treatment; it increases just prior to actual treatment, then decreases and levels off. Outward hostility tends to increase at the time of post sham treatment, then dips and remains quite stable. Hope as measured by the content analysis of verbal behavior is related to satisfactory human relations in the patient's life situation.

## USE OF AUTOLOGOUS BONE MARROW TRANSPLANTATION

Because of radiation-induced hematologic depression, autologous bone marrow storage and reinfusion were instituted in 1964. Employing the method of Kurnick<sup>28</sup> marrow was removed from the posterior iliac crest under local anesthesia, to an average value approximating 300 cc. It was mixed with Osgood-glycerol medium and stored at -83° centigrade following a programmed temperature reduction of 1° centigrade per minute. Prior to reinfusion dextrose was added, and then the marrow was given intravenously, initially without filtration, at a rate of 50 to 60 cc per minute. The first two patients who received a marrow transfusion in our study, numbers 051 and 053, were infused with frozen marrow 24 and 19 days post irradiation respectively, at a time when the marrow sinusoids were relatively empty of precursor cells, with the expectation that there would be more room for the transplant to take. Marrow viability in these two procedures was 55% and 57%.<sup>45</sup>

Patient number 051 experienced moderate hemoglobinuria not seen in patient 053 after infusion. Marrow was given in both cases 2 to 3 weeks post irradiation; hence it was impossible to distinguish spontaneous marrow recovery from successful marrow autotransfusion.

Because hemoglobinuria had been noted a triple filter system was developed and marrow autotransplantation on patient 070, 077, 078, 087, 090, 091, 095, 098, 099, 107 and 111 have all been performed employing this filter system.<sup>48</sup>

In marrow transplants of patients 070, 077, and 078, the delay between the removal of marrow and transfusion was 11, 2 and 0 days, respectively. The platelet count of patient 078 never fell below 125,000 per cubic millimeter, but the white blood count dropped as low as 900, suggesting possible effectiveness of the technique for the first time.

For the next 8 patients the technique was therefore modified so that a larger volume of marrow (500 cc) was removed from the patient under general anesthesia. The patient was then irradiated and the marrow replaced intravenously on the same day as it was removed. The results in Table 7 indicate the success attendant on the modification of this procedure. Five patients receiving 200 rads of whole body radiation showed mean white counts to be  $2820 \pm 804$  cells per cu mm at the nadir. In 7 patients given the same dose but no autograft, the level at the nadir was  $850 \pm 380$  cells per cu mm, the two means being significantly different (Table 8). The first patient transplanted with our new technique (patient 087) was followed in the Clinical Research Center, Cincinnati Children's Hospital, for over 6 weeks without any evidence of illness. Subsequently patients receiving these whole body doses have only been hospitalized for a total of 5 days or less. The degree of marrow depression in the successfully transplanted patient is such that hemorrhage and infection are not observed.

The three failures in the revised transplantation technique have been patient 090, 099 and 107. Patient 090 suffered a cerebrovascular accident unrelated to her tumor or her radiotherapy. The latter two patients (099, 107) had had widespread radiotherapy which had affected

the reticuloendothelial framework necessary for stem cell development, and preliminary cell aspirates in allegedly unirradiated areas did appear hypocellular. Patient 107 appeared to possess normal granulocyte reserves, one of our marrow screening parameters, only because we were given an incorrectly high body weight on which to base our etiocholanolone dosage, thus falsely elevating the marrow granulocyte reserves. From this unfortunate experience we now insist that a candidate for marrow autotransplantation have a normal iliac marrow aspirate histologically, a normal bone marrow scan employing technetium-99m sulfur colloid, and normal granulocyte reserves measured with etiocholanolone (after we weigh the patient) as indicators of normal marrow function. At autopsy, patient 099, who died on day 31 post radiation, had widespread carcinoma of the pancreas. Patient 107 survived her pancytopenia without any evidence of sepsis. Patient 111 had no significant cytopenia and her hospitalization (including autotransplant) lasted only 4 days.

This technique has been of advantage in simplifying the patient's course and eliminating the long period of hospitalization needed prior to transfusion. The possibility of reinfusing tumor cells in the untreated marrow exists, but the elimination of this problem awaits the development of successful methods of marrow allotransplantation.

## SUMMARY

1. Whole and/or partial body radiation therapy given in single doses has shown beneficial effects in the control of certain advanced cancers. The palliative effects compare favorably with results using anti-cancer drugs as commonly reported in the medical literature.

Radiation certainly seems to improve survival in the untreated patient with cancers of colon, lung and breast.

2. The use of autologous marrow reinfusion immediately after radiation therapy minimizes the characteristic marrow depression otherwise observed. The degree of illness following infusion is greatly lessened and hospitalization greatly shortened.

Table 1

CANCER OF COLON - ALL CASES BY LENGTH OF SURVIVAL  
OF ADVANCED DISEASE (29 PATIENTS)

Study No.*	Age	Sex/Race	Survival After D <sub>x</sub> (days)	Survival After R <sub>x</sub> (days)	Dose** (rads)
106	58	F / W	40	25	300 LB
109	56	M / W	116	80	300 LB
052	60	M / W	120	91	200 LB
033	64	M / N	126	86	100
082	49	F / N	136	33	300 LB
015	61	M / N	143	32	100
007	62	M / N	181	121	100
067	52	F / N	192	163	100 LB
049	75	M / N	213	169	200 LB
050	80	M / N	220	197	200 UB
036	64	M / N	261	238	100
064	54	F / N	262	188	300 LB
091	62	F / W	295	52	200
063	38	M / W	299	244	300 LB
066	63	M / N	327	203	200 LB
107	58	F / W	347	89	200
047	57	M / W	411	147	150 LB
111	52	F / N	434	307	200
062	60	M / N	451	270	150
096	42	M / N	583	439	100
113	72	F / N	632	381	100
098/103	45	F / N	912	474	200 + 300 LB
020	69	F / N	946	885	200
006	67	M / W	982	740	54
101	76	M / N	983	864	257 LB
100	76	M / N	1258	900	300 LB
023	44	M / N	1261	651	200
095/104	66	F / N	1437	704	200 + 300 LB
108	66	F / W	1691	584	300 UB

\*Study No. refers to the roster of patients described serially in Technical Reports: Nos. 6-1540, 18-2941, 31-3642, 6-6443, 66-7044, 77-8245, 83-9146, 92-10347, 104-11148, 112-113 personal communication; ELS.

\*\*Dose in rads at the midline. Where no letter follows the dose, whole body radiation was given. LB is lower body radiation; UB is upper body radiation. The dividing point is the xiphoid.

Median Survival - 327 days

Table 2

CANCER OF COLON - CASES WITH METASTASES TO LIVER  
(22 PATIENTS)

Study No.*	Survival After D <sub>x</sub> (days)	Survival After R <sub>x</sub> (days)
106	40	25
109	116	80
052	120	91
033	126	86
082	136	33
015	143	121
067	192	163
036	261	238
091	295	52
066	327	203
107	347	89
111	434	307
062	451	270
096	583	439
113	632	381
098	912	474
006	982	740
101	983	864
100	1258	900
023	1261	651
095	1437	704
108	1691	584

Median Survival - 391 days

\*See footnote to Table 1

Table 3

LUNG CANCER - SURVIVAL IN DAYS AFTER D<sub>x</sub>  
(15 PATIENTS)

Study No. *	Survival in Days after D <sub>x</sub>	Survival in Days after R <sub>x</sub>	Dose (rads)
053	57	28	200
056	103	38	100 UB
086	116	20	100
078	126	61	200
088	135	7	150
081	144	24	100
051	163	74	150
070	193	68	150
102	266	22	200 Trunk
018	333	298	200
044	349	196	100
011	419	323	100
112	683	403	100
025	797	33	150
084/097	855	643	300 UB + 100

Median Survival - 193 days

\*See footnote to Table 1

Table 4

CANCER OF BREAST - SURVIVAL POST D<sub>x</sub>  
(15 PATIENTS)

Study No.*	Survival Post D <sub>x</sub> (days)	Survival Post R <sub>x</sub> (days)	Dose (rads)
089	101	16	200 Trunk
055	175	156	200 UB
029	285	152	150
060	316	30	150
045	138	25	150
022	473	10	150
094	473	354	150 Trunk
031	479	446	100
079	554	209	100
010	783	48	100
008	1056	91	100
035	1068	859	150
040	1095	1063	100
083	1098	264	100
092	1308	1143	150 Trunk

Median Survival - 479 days

\*See footnote to Table 1

Table 5

INCIDENCE OF NAUSEA AND VOMITING IN 88 CANCER PATIENTS  
RECEIVING WHOLE AND/OR PARTIAL BODY RADIATION THERAPY

	<u>Patients</u>	<u>Percent</u>
No Nausea nor Vomiting	39	44
Nausea and/or Vomiting up to 3 hours after R <sub>x</sub>	23	27
Nausea and/or Vomiting up to 6 hours after R <sub>x</sub>	12	14
Nausea and/or Vomiting up to 12 hours after R <sub>x</sub>	3	3
Nausea and/or Vomiting up to 24 hours after R <sub>x</sub>	7	8
Nausea and/or Vomiting up to 48 hours after R <sub>x</sub>	0	--
Nausea and/or Vomiting 48 hours +	4	4
	<hr/>	<hr/>
	88	100

Table 6

PALLIATIVE EFFECTS\* OF TREATMENT  
IN 85 PATIENTS\*\*

Relief of pain	31%
Decrease in tumor size	31%
Increase in activity	13%
Increase in well being (weight gain, appetite improvement, subjective statement by patient)	30%
<u>One or more of the above</u> -----	<u>56%</u>
No change	31%
Lost to follow-up for evaluation of palliation	4%
Death between 20 and 60 days possibly attributable to radiation	9%

\*In some of the patients there were more than one indication of improvement. Thus the percentages exceed 100%.

\*\*3 children with Ewing's tumor received prophylactic treatment and are not included in this analysis.

Table 7  
WHOLE BODY RADIATION WITH MARROW TRANSPLANTATION

Study No.*	Type Transplant	Whole Body Dose (rads)	Date Marrow Removed	Date of Rx	Date Marrow Reinfused	No. Cells Reinfused	Viability	Marrow Frozen	Complications of Infusion	Outcome of Autograft
051	Auto	150	4/26/65	5/1/65	5/25/65	1.6 x 10 <sup>9</sup>	55%	Yes	**Hemoglobin-uria for 1 day	Did not take
053	Auto	200	5/4/65	5/8/65	5/27/65	1.4 x 10 <sup>9</sup>	57%	Yes	**None	Did not take
070	Auto	150	5/4/65	3/2/67	3/13/67	0.33 x 10 <sup>9</sup>	68%	Yes	None	Did not take
077	Auto	200	10/31/67	11/7/67	11/9/67	0.79 x 10 <sup>9</sup>	48%	Yes	Hemoglobin-uria for 12 hours	Did not take
078	Auto	200	11/4/67	12/5/67	12/5/67	4.16 x 10 <sup>9</sup>	96%	No	None	Possible per-tial take with platelets never below 125,000/mm <sup>3</sup> but wbc 900/mm <sup>3</sup>
087	Iso	200	3/3/69	2/27/69	3/3/69	4.38 x 10 <sup>9</sup>	99%	No	None	Take
090	Auto	150	2/2/69	2/2/69	2/2/69	15.6 x 10 <sup>9</sup>	96%	No	None	Cerebrovascular Accident killed patient 6th day after Rx
091	Auto	200	7/2/69	7/2/69	7/2/69	4.6 x 10 <sup>9</sup>	98%	No	None	Take
095	Auto	200	11/5/69	11/5/69	11/5/69	3.07 x 10 <sup>9</sup>	97%	No	None	Take
098	Auto	200	1/27/70	1/27/70	1/27/70	7.42 x 10 <sup>9</sup>	98%	No	Transient Hypotension before Infusion	Take
099	Auto	230	3/3/70	3/3/70	3/3/70	5.32 x 10 <sup>9</sup>	95%	No	None	No take
107	Auto	200	12/15/70	12/15/70	12/15/70	3.2 x 10 <sup>9</sup>	95%	No	None	Take doubtful-leukopenia but no sepsis
111	Auto	200	5/19/71	5/19/71	5/19/71	7.4 x 10 <sup>9</sup>	96%	No	None	Take

\*See footnote to Table 1

Table 8

RESULTS OF SUCCESSFUL ISO- AND AUTO-TRANSPLANTS OF  
Marrow AFTER 200 RADS MIDLINE WHOLE BODY RADIATION

<u>Study No.</u>	<u>Day of Leukocyte Nadir</u>	<u>Leukocyte Count at Nadir (cells/cu.mm.)</u>	<u>Nucleated Cell Count Infused Per Kilogram Body Weight **</u>
087	26	2100	$1.6 \times 10^8$
091	25	4100	$2.3 \times 10^8$
095	33	2700	$0.6 \times 10^8$
098	28	2200	$1.7 \times 10^8$
111	31	3000	$1.4 \times 10^8$
Mean	28.6	$2820 \pm 804^+$	$1.5 \times 10^8$
Mean of Controls*	24	$850 \pm 380^+$	--

• 7 patients receiving 200 rads whole body radiation without transplantation of marrow.

+ The means differ significantly by the t test at  $p < 0.001$  and by the Wilcoxon two sample test at  $p < 0.02$ .

\*\* It has been estimated that  $1.1 \times 10^7$  cells/kg. are required for a successful marrow iso- or autotransplant (48).

FIGURE 1





FIGURE 2



The survival by actuarial analysis is shown for a total of 61 patients who presented between December 1961 and June, 1964 at Cincinnati General Hospital. The only patients excluded from this group are those in whom distant metastases were present at the time of diagnosis (17 patients). If they were to be included, the 1 year survival figure would drop to about 7 per cent. It is emphasized that these figures take account of all cases seen (including those apparently "early" and amenable to complete surgical resection). Although other reported figures may be somewhat higher, differences are more realistically attributable to biologic factors rather than to therapy.

From Horwitz et al., Am. J. Roent., Rad. Ther., Nuc. Med., 1965, 93: 615-638.

FIGURE 3





FIGURE 4



## REFERENCES

1. Andrews, G.A., Comas, F.V., Edwards, C.L., Kniseley, R.M., Lushbaugh, C.C. and Vodopick, Helen. Hematologic and therapeutic effects of total-body irradiation (50R-100R) in patients with malignant lymphoma, chronic lymphocytic and granulocytic leukemias, and polycythemia vera. (USAEC, Division of Technical Information Extension, Oak Ridge, Tennessee, ORAU-112, Biology and Medicine (TID-4500), 1970, (December).
2. Bahnson, C.B. ed., Second Conference on Psychophysiological Aspects of Cancer. Ann. N.Y. Acad. Sci. 1969, 164:307-634.
3. Bortin, M. A compendium of bone marrow transplantation. Transplantation 1970, 9:571-587.
4. Buckner, C.D., Epstein, R., Rudolph, R., Clift, R., Storb, R., and Thomas, E. Allogenic marrow engraftment following whole body irradiation in a patient with leukemia. Blood, 1970, 35:741-750.
5. Beierwaltes, W.H., Haynie, T.P., and Nofal, M.M. Treatment of thyroid carcinoma with <sup>131</sup>I. Results at fourteen years. JAMA, 1963, 183:303.
6. Campbell, A., Godlee, J.N., Emery, E.W. and Pranker, T.A. Diagnosis and treatment of primary polycythemia. Lancet, 1970, 1:1074-1077.
7. Chaoul, H. and Lange, K. Ueber lymphogranulomatose und ihre Behandlung mit Rontgenstrahlen. Munchen Med. Wchnschr. 1923; 70:725-727.
8. Chen, I-Wen, Kereiakes, J.G., Friedman, B.I., Saenger, E.L. Radiation-induced urinary excretion of deoxycytidine by rats and humans. Radiology (August), 1968, 91:(2)343-348.
9. Collins, V.P. and Loeffler, R.K. The therapeutic use of single doses of total body radiation. Am. J. Roent. 1956, 75:542-547.
10. Corwin, S.H. Phosphorus 32 in advanced carcinoma of the prostate. J. Urol. 1970, 104:745-748.
11. Gottschalk, L.A., Kunkel, R., Wohl, T.H., Saenger, E.L., Winget, C.N. Total and half body irradiation: effect on cognitive and emotional processes. Arch. Gen. Psychiat. 1969, 21:574-580.
12. Higgins, G.A., Dwight, R.W., Smith, J.V., Keehn, R.J. Fluorouracil as an adjuvant to surgery in carcinoma of the colon. Arch. Surg. (April), 1971, 102:339-343.
13. Hollcroft, J., Lorenz, E., and Hurstiger, H. Effect of ionizing radiations on a transplanted lymphosarcoma. J. Nat. Cancer Inst. 1950, 11:1-16.

14. Hollcroft, J., Lorenz, E. and Matthews, M. Factors modifying the effect of x-irradiation on regression of transplanted lymphosarcoma. J. Nat. Cancer Inst., 1952, 12:751-763.
15. Hollcroft, J. and Matthews, M. Effect of ionizing irradiation treatments on tumor regression. J. Nat. Cancer Inst., 1953, 14:527-535.
16. Horwitz, H., Wright, T.L., Perry, H., and Barrett, C.M. "Suppressive" chemotherapy in bronchogenic carcinoma - A randomized prospective clinical trial. Am. J. Roent., Rad. Therapy & Nuc. Med., 1965, 93: 675-638.
17. Jacobs, E.M., Reeves, W.J., Wood, D.A., Pugh, R., Braunwald, J., and Bateman, J.R. Treatment of cancer with weekly intravenous 5-fluorouracil. Cancer, (June), 1971, 27:1302-1305.
18. Jacobson, L.O., Marks, E.K., Robson, M.J., Gaston, E., and Zirkle, R.E. The effect of spleen protection on mortality following x-irradiation. J. Lab. Clin. Med., 1949, 34:1538-1543.
19. Jacobson, L.O., Simmons, E.L., Marks, E.K., and Eldredge, J.H. Recovery from radiation injury. Science, 1951, 113:510.
20. Jaffe, B.M., Donegan, W.L., Watson, F. and Spratt, J.S. Factors influencing survival in patients with untreated hepatic metastases. Surg. Gynecology & Obst., 1968, 127:1-11.
21. Jenkin, R.D.T., Rider, W.D. and Sonley, M.R. Ewing's sarcoma - a trial of adjuvant total-body irradiation. Radiology, 1970, 96:151-155.
22. Johnson, R.E. Ray of hope in lymphosarcoma. Medical World News, 9 (January), 1970.
23. Johnson, R.E. Total body irradiation of chronic lymphocytic leukemia: incidence and duration of remission. Cancer, (March), 1970, 25:523-530.
24. Johnson, R.E. Total-body irradiation with fractionated dosage schedules. Frontiers of Radiation Therapy & Oncolog., 1968, 3:152-162, New York, S. Karger, Basel.
25. Johnson, R.E., Foley, H.T., Swain, R.W. and O'Connor, G.T. Treatment of lymphosarcoma with fractionated total-body irradiation. Cancer, 1967, 20:482.
26. Johnson, R.E., O'Connor, G.T., Levin, D. Primary management of advanced lymphosarcoma with radiotherapy. Cancer, 1970, 25:787-791.

27. Kereiakes, J.G., Van de Riet, W., Born, C., Ewing, C., Silberstein, E.B., and Saenger, E.L. Active bone-marrow dose related to hematological changes in whole-body and partial body  $^{60}\text{Co}$  gamma radiation exposures. *Radiology*, 1972, 103:651-656.
28. Kurnick, N.B. Autologous and isologous bone marrow storage and infusion in the treatment of myelosuppression. *Transfusion*, 1962, 2:178-187.
29. Lahiri, S.R., Boileau, G., Hall, T.C. Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth. *Cancer*, (October), 1971, 28:902-906.
30. Loeffler, R.K., Collins, V.P., Hyman, G. Comparative effects of total body irradiation, nitrogen mustard and triethylenemelamine on the hematopoietic system of terminal cancer patients. *Science*, 1953, 118:161-163.
31. Maxfield, J.R., Jr. The use of radioactive phosphorus and testosterone in the treatment of metastatic lesions in bone from breast and prostate. *Int. J. Appl. Radiat.*, 1956, 1:133.
32. Medinger, F.G. and Craver, L.F. Total body irradiation with review of cases. *Am. J. Roentgenol.*, 1942, 48:651-671.
33. Milburn, L.F., O'Grady, L., and Hendrickson, F.R. Radical radiation therapy and total body irradiation in the treatment of Ewing's sarcoma. *Cancer*, 1968, 22:919-925.
34. Mukherji, B., Yagoda, A., Oettgen, H.F., and Krakoff, I.H. Cyclic chemotherapy in lymphoma. *Cancer*, (October), 1971, 28:886-893.
35. Parsons, J.A., Webster, J.H. and Dowd, J.E. Evaluation of the placebo effect in the treatment of radiation sickness. *Acta Radiologica*, 1961 56:129-140.
36. Pegg, D.E. Bone marrow transplantation. Year Book Medical Publishers, Chicago, Illinois, 1966, pp. 102-112.
37. Pestana, C., Reitemeier, R., Moertel, C., Judd, E. and Dockertey, M. The natural history of carcinoma of the colon and rectum. *Am. J. Surg.*, 1964, 108:826.
38. Rapoport, A. and Burleson, R. Survival of patients treated with systemic fluorouracil for hepatic metastases. *Surg. Gynecology & Obst.*, 1970, 130:773-777.
39. Rider, W.D. and Hasselback, R. The symptomatic and hematological disturbance following total body radiation of 300 rad gamma-ray irradiation. In International conference on Guidelines to Radiological Health, published as #999-RH-33, U.S. Bureau of Radiological Health, USPHS, Rockville, Maryland, 1968, pp. 139-144.

40. Saenger, E.L. Metabolic changes in humans following total body irradiation. Report for period February, 1960, through October, 1961. Defense Atomic Support Agency Report.
41. Saenger, E.L. Metabolic changes in humans following total body irradiation. Report for period November, 1961, through April, 1963. Defense Atomic Support Agency Report, DASA 1422.
42. Saenger, E.L., Friedman, B.I., Kereiakes, J.G. and Perry, H. Metabolic changes in humans following total body irradiation. Report for period May, 1963, through February, 1964. Defense Atomic Support Agency Report, DASA 1633.
43. Saenger, E.L., Friedman, B.I., Kereiakes, J.G. and Perry, H. Metabolic changes in humans following total body irradiation. Report for period February, 1960, through May, 1966. Defense Atomic Support Agency Report, DASA 1844.
44. Saenger, E.L., Friedman, B.I., Horwitz, H., Kereiakes, J.G., and Perry, H. Metabolic changes in humans following total body irradiation. Report for period May, 1966, through April, 1967. Defense Atomic Support Agency Report, DASA 2179.
45. Saenger, E.L., Friedman, B.I., Horwitz, H. and Kereiakes, J.G. Radiation effects in man: manifestations and therapeutic efforts. Report for period May, 1967, through April, 1968. Defense Atomic Support Agency Report, DASA 2168.
46. Saenger, E.L., Silberstein, E.B., Horwitz, H., Kereiakes, J.G., Chen, I-Wen, Winget, C., Gleser, G.C. and Kunzel, R.L. Radiation effects in man: manifestations and therapeutic efforts. Report for period May, 1968, through April, 1969. Defense Atomic Support Agency Report, DASA 2428.
47. Saenger, E.L., Silberstein, E.B., Aron, B.S., Horwitz, H., Kereiakes, J.G., Chen, I-Wen, Winget, C., and Gleser, G.C. Radiation effects in man: manifestations and therapeutic efforts. Report for period May, 1969, through April, 1970. Defense Atomic Support Agency Report, DASA 2599.
48. Saenger, E.L., Silberstein, E.B., Aron, B.S., Horwitz, H., Kereiakes, J.G., Chen, I-Wen, Winget, C., and Gleser, G.C. Radiation effects in man: manifestations and therapeutic efforts. Report for period May, 1970, through April, 1971. Defense Nuclear Agency (formerly Defense Atomic Support Agency) Report DNA 2751 T.
49. Samp, R.J. and Ansfield, F.J. Breast cancer treated with fluorouracil. JAMA, 1966, 198:724-730.

50. Silberstein, E.B., Chen, I-Wen, Saenger, E.L., Kereiakes, J.G. Cytologic-biochemical radiation dosimeters in man, in Biochemical Indicators of Radiation Injury in Man. International Atomic Energy Agency, Vienna, 1971, pp. 181-214.
51. Stearns, M. and Binkley, G. Palliative surgery for cancer of the rectum and colon. *Cancer*, 1954, 7:1016.
52. Subcommittee on Breast and Genital Cancer. Androgens and estrogens in the treatment of disseminated mammary carcinoma - retrospective study of 949 patients. Council on Drugs. *JAMA*, 1960, 172:1271-1283.
53. Thomas, E.D., Buckner, C.D., Rudolph, R.H., Fefer, A., Storb, R., Neiman, P., Bryant, J., Chard, R., Clift, R., Epstein, R., Fialkow, P., Funk, D., Giblett, E., Lerner, K., Reynolds, F., and Slichter, S. Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. *Blood*, (September), 1971, 38:267-287.

## SECTION 2

### Thermography as a Radiobiological Dosimeter

Biological indicators of radiation injury may not always have the same degree of precision as that available from physical dosimeters (1). However, the former may often be available with greater rapidity to the clinician who requires estimates of the absorbed dose to establish the degree and extent of radiation injury and hence his patients prognosis.

The effect of radiation on the skin was historically the first biological indicator employed (2) and the skin erythema dose, or S.E.D., became the unit of measurement of absorbed radiation dose (3). This dose effect is dependent on the area irradiated, the energy, quality, dose rate and depth dose of the radiation employed (4).

Infra-red thermography has been employed with some success in the diagnosis of numerous medical conditions (5-9). Biophysical aspects of this technique have been reviewed elsewhere (10).

The purpose of this study has been to determine if thermography, a technique with sensitivity to temperatures changes of fractions of a degree, could detect early skin-temperature changes in patients receiving radiotherapy.

#### Materials and Methods

Six patients receiving cobalt-60 radiotherapy for a variety of malignant neoplasms were scanned serially with an infra-red sensitive thermograph during the course of treatment. Informed consent was obtained from each individual. These individuals were instructed to take no medication for 24 hours prior to the study. None had smoked a cigarette or

ingested hot or cold beverages for 2 hours prior to thermography. Clothing was removed from the area of the body to be studied in a closed room with temperature maintained at  $73 \pm 1^{\circ}\text{F}$ . A twenty minute period was allowed for thermal equilibrium (10). The patient lay supine or prone on a table during the study and the infra-red radiation emitted by his body was reflected into a Barnes/Bofors Model M-101 Medical Thermograph by a front-silvered mirror angled above him. The radiation was converted to an electrical signal used to produce visible light photographed by a Polaroid camera.

Symmetric areas on each patient body one inch square were measured from the midline to correspond exactly to the irradiated region and were marked with indelible ink. Thermograms were first obtained from the skin 20 minutes after the marking process, and then slender pieces of aluminum foil were overlaid on the ink mark delineating each area. The margins of these symmetrical regions appeared as dark lines on this second thermogram because of the low emissivity of the shiny surface. The outlined areas on the second thermogram were initially transferred to the first picture by superimposing the Polaroid films and punching pin holes along the border of the outlined area. It was subsequently determined during these experiments that the thin boundaries of foil did not change the temperature of the enclosed skin.

A pre-calibrated thermal gray scale, containing squares of known constant temperature from  $29^{\circ}\text{C}$  through  $38^{\circ}\text{C}$  was positioned to appear on each scan. The temperature of each square was unchanged on recalibration by the manufacturer, confirming the validity of using this scale for

measuring heat emission.

Densitometer readings were obtained from the thermal gray scale and plotted against the temperature reading of this scale. The resultant curve was used to obtain the skin temperatures of the two sides of the body being compared from the densitometer readings of the one inch square areas seen in the thermograph. Two densitometers were employed\*+ but gave identical readings for each picture. A new temperature - densitometry curve was plotted for each thermogram examined. Maximum error attributable to the densitometer, obtained from multiple readings of the same areas of selected thermograms was  $0.133^{\circ}\text{C}$  (mean  $\pm$  2 S.D.). The thermography equipment which we employed had no intra-thermogram drift according to the manufacturer and the inter-thermogram drift was said to be linear.

Since patients were followed throughout their radiotherapy, the variables of number of fractions and total time relative to total dose made any simple summation of accumulated dose difficult to evaluate. The concept of nominal standard dose (N.S.D.) was therefore employed to correlate the biologic effect of radiation dose with skin temperature (11). The N.S.D. is employed as the best available estimate of the equivalent single dose. Ellis finds the total dose,  $D = (\text{N.S.D.}) (T^{0.11}) (N^{0.24})$  where D and (N.S.D.) are in rads, T is in days, and N is the number of the fractions.

---

\*Barnes Engineering Co., 30 Commerce Rd., Stamford, Connecticut 06902

+Quantalog Model TD 100, Macbeth Instrument Corp., P.O. Box 950, Newburgh, N.Y.

From 13 healthy volunteers (5 women, 8 men, ages 17 to 48) each of whom had multiple thermographs taken on separate days, we established the normal upper limits (mean  $\pm$  2 S.D.) of the difference between symmetric areas of the trunk. The data in Table 1 correspond well with the approximations of others (10,12,13). Variation in skin pigmentation does not affect infra-red radiation from the body (10). We found no differences in thermal symmetry between men and women.

### Results and Discussion

Table 1 indicates those limits which, when exceeded, indicate a significant difference between symmetric area ( $p < 0.05$ ) when studies with the above techniques.

The results of thermographic determinations on irradiated and the corresponding symmetric non-irradiated areas for each of our patients are listed in Table 2, with the type of malignancy for which each was receiving cobalt-60 radiotherapy.

Patients 2 and 6 had thermal asymmetry exceeding the upper limits for normals listed in Table 1 prior to irradiation, but patients prior to irradiation cannot be considered normal, both because of untreated tumor and previous surgery in these areas. These factors naturally will cause deviations from the normal degree of thermal asymmetry. Nevertheless, the normal asymmetry values in Table 1 were exceeded only two times pre-irradiation.

With nominal standard - or single-doses up to 1453 rads (patient 5) we were unable to detect significant differences between irradiated and non-irradiated sides with the thermograph. In none of these patients was

there visible erythema or subjective discomfort in the irradiated area.

The direct heat imparted to the skin from gamma rays, even assuming total absorption, is itself negligible and may be calculated as  $2.39 \times 10^{-6}$  °C per rad (14).

For several of our patients we obtained thermographic readings for a number of stages of their radiotherapy. For those patients we attempted to determine the correlation between radiation dose and the difference in temperature between the irradiated and non-irradiated sides ( $\Delta T$ ). The correlations were generally low. We obtained occasional high correlations but they were both positive and negative. For example, patient one, with a N.S.D. of 962 rads had a correlation of -0.87 for a region within his posterior lumbo-sacral area, while patient six, with a N.S.D. of 946 rads, had a correlation of +0.73 for an area in his anterior upper abdomen. Hence, no correlation can be drawn between radiation doses and the  $\Delta T$  at radiation doses up to 1000 rads. In all cases where the correlation appeared high, the  $\Delta T$  did not exceed the upper limit for normal thermal asymmetry.

In the only case with a N.S.D. exceeding 1000 rads of  $^{60}\text{Co}$  irradiation to the trunk, an abnormal  $\Delta T$  occurred: patient 5, with N.S.D. of 1453 rads, receiving radiation to the abdomen.

During the brief period of availability of the thermograph only one patient was receiving 250 kVp X-ray therapy. Her N.S.D. was 1930 rads (Table 3) but the contribution of active superficial breast cancer to the abnormally high  $\Delta T$  of 1.40°C prevents any conclusion as to dose-response

relationship of this quality of radiation and skin temperature.

The threshold erythema dose for various qualities of radiation rises with the energy applied (14) and is given as 960 rads for 1 meV. Our limited human data are in agreement, with no significantly abnormal  $\Delta T$  at doses under 1000 rads. The one patient whose skin temperature did rise significantly to exceed our normal values received the highest N.S.D. to his trunk, 1453 rads.

Thus, sophisticated thermographic equipment may add little to the doses one can estimate by visible erythema. We have assumed that the nominal standard dose is the equivalent of a single dose. The N.S.D. as calculated herein correlates well with erythema doses reported elsewhere (14).

Skin changes in man do not appear to be a good early biologic radiation dosimeter. The effects of doses to the trunk well below those we can detect with thermography will be apparent from early gastro-intestinal and hematologic changes (15).

TABLE 1

NORMAL MAXIMUM DIFFERENCES IN SYMMETRIC AREAS  
OF THE BODY

---

Head - Neck	1.0° (10)
Anterior Chest	0.78°
Posterior Chest	1.23°
Anterior upper abdomen (xiphoid to umbilicus)	1.38°
Anterior lower abdomen (umbilicus to pubis)	1.42°
Lumbosacral region	1.42°

TABLE 2

SKIN TEMPERATURE OF PATIENTS RECEIVING COBALT-60 RADIOTHERAPY  
(DEGREES CENTRIGRADE)

Patient 1 - Testicular Seminoma

Posterior lumbo-sacral:

Right Rad		Left Non-Rad		ΔT		NSD
*U	*L	U	L	U	L	
33.25	33.70	32.70	32.90	0.55	0.80	674.1
33.50	34.05	34.10	33.60	-0.60	0.45	961.9

\*U = upper, L = lower part of irradiated area, each 1 inch square

Correlation NSD and T: L:r=0.41 U:r=0.87  
ΔT insignificant throughout.

Patient 2 - Bronchogenic Carcinoma

Chest:

Left Rad		Right Non-Rad		ΔT		NSD
U	L	U	L	U	L	
34.80	33.85	33.85	33.45	0.95	0.40	0
35.15	34.45	34.70	34.35	0.45	0.10	861.5

Correlation NSD and T: U: r=0.19 L:r=0.45  
ΔT insignificant throughout.

TABLE 2  
(continued)

Patient 3 - Renal Carcinoma

Upper Abdomen:

		Left Non-Rad		Right Rad		NSD	ΔT	
		U	L	U	L		U	L
Post.	[	36.25	36.30	36.10	35.65	473.1	0.15	0.65
Ant.	[	33.65	33.65	33.15	33.45	473.1	0.50	0.20

ΔT's not significant

Patient 4 - Bronchogenic Carcinoma

Anterior Chest:

		Left Rad				Right Non-Rad				ΔT				NSI
		*UL	UM	LL	LM	UL	UM	LL	LM	UL	UM	LL	LM	
Ant.		34.00	34.70	34.30	35.35	33.40	34.60	34.40	34.95	.60	.10	.90	.40	96
Post.		34.35	35.15	34.30	35.30	34.00	34.80	34.50	35.55	.35	.35	-.20	-.25	96

\*UL = upper lateral, UM = upper-medial, LL = lower lateral, LM = lower median  
ΔT's not significant

TABLE 2  
(continued)

Patient 5 - Malignant Melanoma

Anterior Abdomen:

Rad				Non-Rad				NSD	ΔT			
*UL	UM	LL	LM	UL	UM	LL	LM		UL	UM	LL	LM
34.60	35.25	--	35.40	34.05	33.90	--	33.75	1452.6	0.55	1.35	--	1.75

\*UL = upper lateral, UM = upper median, LL = lower lateral, LM = lower median areas in field.

The ΔT for the UM and LM are statistically significant.

Patient 6 - Bronchogenic Carcinoma, Metastatic

Anterior Upper Abdomen:

Rad		Non-Rad		ΔT		NSD
U	L	U	L	U	L	
33.20	33.65	34.24	34.00	-1.05	-0.35	0
33.20	33.30	33.25	33.00	-0.05	-0.30	945.7

Correlation between NSD and T: LM: r=0.74 UM r=0.73

ΔT insignificant throughout radiation period ( $\Delta T \leq .30$ )

TABLE 3

BREAST CARCINOMA  
250 kVp X-ray  
Anterior Chest

Rad	Non-Rad	MSD	$\Delta T$
35.40	34.00	1930.2	1.40

This  $\Delta T$  is significant

REFERENCES

1. Biochemical Indicators of Radiation Injury in Man, International Atomic Energy Agency, Vienna, 1971, pp.320.
2. Strandquist, M. A Study of the Cumulative Effects of Fractionated X-ray Treatment Based on Experience Gained at the Radiumhemmet with the Treatment of 280 cases of the Skin and Lip. Acta. Radiol. 55: 300, 1944.
3. Lushbaugh, C.C. Reflections on Some Recent Progress in Human Radiobiology, Vol. 3, Academic Press, New York, 1969, pp. 277-314.
4. Radiation Effects in Man: Early Effects, Chapter 5 in Radiobiological Factors in Manned Space Flight,; W.H. Langham, Ed., National Academy of Sciences, National Research Council, Washington, D.C., 1967, pp. 59-75.
5. Patil, K.D., Williams, J.R., Williams, K.L., Thermographic Localization of Incompetent Perforating Veins in the Leg. Br. Med. J. 1:195-197, (24 January), 1970.
6. Dodd, G.D., Zermeno, A., Marsh, L., Boyd, D., Wallace, J.D., New Developments in Breast Thermography, Cancer 24:(No. 6), 1212-1221, June, 1969.
7. Potanin, C., Thermographic Patterns in Cardio-pulmonary Disease, Med. J. Australia 2:65-70 (11 July), 1970.
8. Birnbaum, S.D., and Kliot, D., Thermoplacentography: Placental Localization by Infrared Sensing Techniques, Obstet. Gynec. 25: 515-519, 1965.
9. Karpman, H.L. Current Status of Thermography, Angiology 21:103-109, 1970.
10. Gershon-Cohen, J., Haberman, J.D., Brueschke, E., Medical Thermography: Summary of Current Status, Radiol. Clin. N. Am. 3:403-431, 1965.
11. Ellis, F., Nominal Standard Dose and the Ret. Br. J. Radiol. 44: 101-108, 1965.
12. Watmough, D.J., Fowler, P.W., Oliver, R. The Thermal Scanning of a Curved Isothermal Surface: Implications for Clinical Thermography. Phys. Med. Biol. 15:1-8, 1970.
13. Draper, J.W., Boag, J.W., The Calculation of Skin Temperature Distribution in Thermography. Phys. Med. Biol. 16:201-211, 1971.
14. Johns, H.E., and Cunningham, J.R. The Physics of Radiology, Third Ed. Charles C. Thomas, Pub., Springfield, Ill., 1969.
15. Saenger, E.L., Effects of Total and Partial Body Therapeutic Irradiation in Man, Proc. First International Symposium on the Biological Interpretation of Dose from Accelerator-Produced Radiation, U.S. Atomic Energy Commission/Div. of Technical Information, CONF-6703 05, 1967, pp. 114-127.